The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

In phase II studies Apatorsen improved outcomes in bladder, prostate cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

OncoGenex Pharmaceuticals Inc. said apatorsen results from two randomized phase II clinical trials were presented at the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

A growing number of prostate cancer experts argue that calling the lowest-risk prostate cancer “cancer” does more harm than good. A UCLA-led study found removing the cancer label could dramatically reduce overtreatment and encourage more men to get screened, potentially leading to significantly fewer deaths from aggressive prostate cancer.
Drugs & Targets

EC approves Padcev + Keytruda as perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer

The European Commission granted Marketing Authorization for Padcev (enfortumab vedotin), in combination with Keytruda (pembrolizumab), as neoadjuvant treatment (before surgery) and then continued after radical cystectomy as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy in the European Union. 
Clinical Roundup

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer, according to the results of a multicenter clinical trial led by researchers at the Johns Hopkins University School of Medicine, Johns Hopkins Kimmel Cancer Center, Department of Radiation Oncology and Molecular Radiation Sciences, and Brady Urological Institute.
Clinical Roundup

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Exploratory analyses of the POTOMAC phase III trial showed adding one year of treatment with AstraZeneca’s Imfinzi (durvalumab) to BCG induction and maintenance therapy reduced the number of high-risk disease recurrences within the first year, with fewer BCG-unresponsive recurrences in patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer compared to BCG treatment alone.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account